Key Abstracts in GU Cancers at ASCO24

Dr. Monty Pal and Dr. Petros Grivas discuss the rapidly evolving management of bladder cancer, including key updates in non-muscle-invasive disease, the integration of novel therapies in the advanced setting, and practical strategies for managing toxicities in clinical practice. ...  Show more

In part two of our miniseries on the global translation gap in oncology, host Dr. Monty Pal and Dr. Regina Barragán-Carrillo explore how ASCO26 Plenary breakthroughs can be adapted to clinical practice in Latin America. Together, they address real-world implementation challenges ...  Show more

Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros ...  Show more

Neeraj Agarwal, MD, FASCO, describes the data from the TALAPRO-2 study on combination talazoparib and enzalutamide for metastatic castration-resistant prostate cancer as presented at the 2023 ASCO GU Cancers Symposium. Dr. Agarwal is a medical oncologist and Presidential Endow ...

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor ...  Show more

The Uromigos met with Andrea Necchi, MD at the 2023 ASCO GU Cancers Symposium to discuss results of the phase 2 KEYNOTE-057 study on the use of pembrolizumab monotherapy for patients with high-risk non-muscle-invasive bladder cancer who are unresponsive to bacillus Calmette–Gu ...